Related Experiment Videos
Blastic phase of chronic myelogenous leukemia
Merat Karbasian Esfahani1, Evelyn L Morris, Janice P Dutcher
1Our Lady of Mercy Comprehensive Cancer Center, 600 East 233rd Street, Bronx, NY 10466, USA. kar1070@yahoo.com
Current Treatment Options in Oncology
|April 18, 2006
Summary
Chronic myelogenous leukemia (CML) can progress to blast crisis (CMLBC), a difficult-to-treat acute leukemia. Current therapies offer limited success, highlighting the need for novel treatment strategies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder.
- CML is characterized by uncontrolled production of mature nonlymphoid cells.
- Progression to acute leukemia (blast crisis) occurs despite the 'chronic' nature of the disease.
Purpose of the Study:
- To review the therapeutic challenges of CML blast crisis (CMLBC).
- To discuss the limitations of current therapies for CMLBC.
- To highlight the need for molecularly targeted treatments.
Main Methods:
- Literature review of CMLBC treatment strategies.
- Analysis of treatment response rates and survival data.
- Discussion of molecular mechanisms underlying CMLBC transformation.
Main Results:
- CMLBC is highly refractory to standard chemotherapy, with response rates below 30%.
- Conventional chemotherapy shows limited success in CMLBC compared to de novo acute leukemia.
- Most CMLBC cases develop in patients already on imatinib therapy, lacking standard treatment options.
Conclusions:
- CMLBC remains a significant therapeutic challenge with a poor prognosis.
- Further research into molecular mechanisms is crucial for developing new targeted therapies.
- Current successful strategies focus on prolonging the chronic phase and delaying blast crisis onset.